LRG1 is an adipokine that mediates obesity-induced hepatosteatosis and insulin resistance

J Clin Invest. 2021 Dec 15;131(24):e148545. doi: 10.1172/JCI148545.

Abstract

Dysregulation in adipokine biosynthesis and function contributes to obesity-induced metabolic diseases. However, the identities and functions of many of the obesity-induced secretory molecules remain unknown. Here, we report the identification of leucine-rich alpha-2-glycoprotein 1 (LRG1) as an obesity-associated adipokine that exacerbates high fat diet-induced hepatosteatosis and insulin resistance. Serum levels of LRG1 were markedly elevated in obese humans and mice compared with their respective controls. LRG1 deficiency in mice greatly alleviated diet-induced hepatosteatosis, obesity, and insulin resistance. Mechanistically, LRG1 bound with high selectivity to the liver and promoted hepatosteatosis by increasing de novo lipogenesis and suppressing fatty acid β-oxidation. LRG1 also inhibited hepatic insulin signaling by downregulating insulin receptor substrates 1 and 2. Our study identified LRG1 as a key molecule that mediates the crosstalk between adipocytes and hepatocytes in diet-induced hepatosteatosis and insulin resistance. Suppressing LRG1 expression and function may be a promising strategy for the treatment of obesity-related metabolic diseases.

Keywords: Diabetes; Endocrinology; Insulin signaling; Metabolism; Obesity.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adipokines / genetics
  • Adipokines / metabolism*
  • Animals
  • Fatty Acids / genetics
  • Fatty Acids / metabolism
  • Fatty Liver / genetics
  • Fatty Liver / metabolism*
  • Glycoproteins / genetics
  • Glycoproteins / metabolism*
  • Humans
  • Insulin Resistance*
  • Mice
  • Mice, Knockout
  • Obesity / genetics
  • Obesity / metabolism*
  • Oxidation-Reduction

Substances

  • Adipokines
  • Fatty Acids
  • Glycoproteins
  • LRG1 protein, human
  • LRG1 protein, mouse